- Theralase’s (TLT) research published in Translational Biophotonics (TBIO), is one of the top 10 most downloaded papers in TBIO
- TBIO is an international peer-reviewed, open access journal dedicated to bridging the gap in translating medical photonic research into clinical practice
- Its amongst work published between January 1, 2019 to December 31, 2020
- Theralase is a clinical stage pharmaceutical company
- Theralase Technologies Inc. (TLT) was up 4.84 per cent, trading at C$0.325 per share at 1:15 pm ET
Theralase’s (TLT) research published in Translational Biophotonics (TBIO), is one of the top 10 most downloaded papers in TBIO.
TBIO is an international peer-reviewed, open-access journal dedicated to bridging the gap in translating medical photonic research into clinical practice. TBIO is a platform for translating photonic methods and technologies in all medical areas to solve unmet medical needs in diagnosis and therapy.
Theralase sponsored research is entitled, “Evaluation of a Ruthenium coordination complex as photosensitizer for Photo Dynamic Therapy (“PDT”) of bladder cancer: Cellular response, tissue selectivity and in vivo response”.
The research demonstrated that the combination of TLD-1433 activated by green laser light resulted in the selective and effective destruction of various cancer cell lines both in-vitro and in-vivo. It includes the complete eradication of urothelial bladder tumors along with protecting normal bladder muscle function.
TLD-1433 is a patented PDC with over 10 years of published peer-reviewed preclinical and clinical research and is currently under investigation in Study II.
Lothar Lilge Ph.D., senior staff scientist UHN comments on the news.
“I am humbled that research, where I was the lead author, became one of the top 10 downloaded papers from TBIO in the 12 months following its publication. The research which I co-authored has now successfully translated from the laboratory bench to clinical studies: firstly, in the successfully completed Theralase Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (safety and efficacy study) and secondly, in the pivotal Theralase Phase II NMIBC clinical study, currently in progress.”
Dr. Arkady Mandel M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer of Theralase also provided his comments.
“These pre-clinical results led a logical progression to our successfully completed Phase Ib NMIBC clinical study. It demonstrates the safety, pharmacokinetics and efficacy in a first in-human clinical study. In the future, I foresee great potential for Theralase Anti-Cancer Therapy to deliver a safe and effective anti-cancer treatment for numerous cancer indications with high unmet needs.”
Theralase is a clinical stage pharmaceutical company. It focuses on the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Theralase Technologies Inc. (TLT) was up 4.84 per cent, trading at C$0.325 per share at 1:15 pm ET.
